Filing Details
- Accession Number:
- 0000950170-24-028795
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2024-03-08 17:31:41
- Reporting Period:
- 2024-03-07
- Accepted Time:
- 2024-03-08 17:31:41
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
1582313 | Xenon Pharmaceuticals Inc. | XENE | Pharmaceutical Preparations (2834) | 980661854 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1619962 | Sherrington Robin | 200 - 3650 Gilmore Way Burnaby A1 V5G 4W8 | Evp, Strategy & Innovation | No | No | No | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Shares | Acquisiton | 2024-03-07 | 1,234 | $9.85 | 9,632 | No | 4 | M | Direct | |
Common Shares | Disposition | 2024-03-07 | 215 | $45.96 | 9,417 | No | 4 | F | Direct | |
Common Shares | Acquisiton | 2024-03-07 | 7,407 | $9.85 | 16,824 | No | 4 | M | Direct | |
Common Shares | Disposition | 2024-03-07 | 1,289 | $45.96 | 15,535 | No | 4 | F | Direct | |
Common Shares | Disposition | 2024-03-07 | 1,019 | $46.15 | 14,516 | No | 4 | S | Direct | |
Common Shares | Disposition | 2024-03-07 | 6,118 | $46.30 | 8,398 | No | 4 | S | Direct |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | M | Direct | |
No | 4 | F | Direct | |
No | 4 | M | Direct | |
No | 4 | F | Direct | |
No | 4 | S | Direct | |
No | 4 | S | Direct |
Reported Derivative Transactions
Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
---|---|---|---|---|---|---|---|
Common Shares | Stock Option (Right to Buy) | Disposition | 2024-03-07 | 1,234 | $0.00 | 1,234 | $9.85 |
Common Shares | Stock Option (Right to Buy) | Disposition | 2024-03-07 | 7,407 | $0.00 | 7,407 | $9.85 |
Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
---|---|---|---|---|---|---|
0 | 2024-03-11 | No | 4 | M | Direct | |
0 | 2024-03-11 | No | 4 | M | Direct |
Footnotes
- The exercise price was converted from $10.78 CAD using the closing rate of exchange of the Bank of Canada on the date of grant, after giving effect to the 1-for-4.86 reverse stock split of the Issuer's outstanding shares effected October 1, 2014 (the "Reverse Stock Split"). The actual exercise price is the Canadian dollar amount regardless of the exchange rate on the date of exercise.
- Represents the closing price of the Company's common shares on March 6, 2024 for purposes of net settlement calculations.
- The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares sold. These share were sold in multiple transactions at prices ranging from $46.15 to $46.17, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein.
- The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares sold. These share were sold in multiple transactions at prices ranging from $46.25 to $46.36, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein.
- The shares subject to this option are fully vested and exercisable.